8-K: Theriva Biologics Completes Enrollment in Phase 2b Pancreatic Cancer Trial

Theriva Biologics has successfully enrolled all 92 targeted patients in its VIRAGE Phase 2b clinical trial for metastatic pancreatic cancer.

Summary

• Theriva Biologics has completed target enrollment of 92 patients in the VIRAGE Phase 2b clinical trial.
• The trial is evaluating VCN-01, an oncolytic adenovirus, in combination with standard chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC).
• VCN-01 is designed to selectively replicate within tumor cells and degrade the tumor stroma.
• The trial is a randomized, controlled study with 46 patients in each arm, comparing VCN-01 plus chemotherapy to chemotherapy alone.
• The primary endpoints are overall survival and VCN-01 safety and tolerability.
• Secondary endpoints include progression-free survival, response rates, and measures of biodistribution and immune response.
• The company is planning regulatory engagements to discuss next steps, including a potential interim data analysis.
• VCN-01 has been administered to 142 patients across all indications to date.
• A previous Phase 1 study showed an 83% overall response rate with a median progression-free survival of 6.3 months and median overall survival of 20.8 months using a single dose of VCN-01 with chemotherapy.

Sentiment

Score: 8

Explanation: The document is positive due to the successful completion of enrollment in the Phase 2b trial, promising Phase 1 results, and regulatory designations. However, the company is still in the clinical stage and faces risks.

Positives

• The company has successfully completed enrollment in the VIRAGE Phase 2b trial, a significant milestone.
• VCN-01 has demonstrated a favorable safety profile and promising efficacy in earlier trials.
• The company has secured Orphan Drug and Fast Track Designations for VCN-01, which could expedite regulatory approval.
• The company has a diverse pipeline of oncolytic virus therapies and a proprietary albumin shield technology.
• The company has a strong leadership team with experience in oncolytic virus development and regulatory affairs.

Negatives

• The company is still in the clinical stage and has not yet generated revenue from product sales.
• The company is dependent on securing additional funding to advance its clinical programs.
• The company faces competition from other companies developing oncolytic virus therapies.
• The company's product candidates are subject to regulatory risks and may not receive approval.
• The company's clinical trials may not achieve the desired results.

Risks

• Clinical trial results may not be consistent with prior results or may not demonstrate sufficient efficacy.
• Regulatory approvals may be delayed or not granted.
• The company may not be able to secure sufficient funding to continue its operations.
• Competitors may develop superior products or therapies.
• The company may not be able to successfully commercialize its products.

Future Outlook

The company plans to engage with regulatory agencies to discuss next steps for VCN-01, including a potential interim data analysis and conversion to a Phase 3 trial. They also plan to initiate commercial scale manufacturing process development.

Management Comments

• Steven A. Shallcross, Chief Executive Officer of Theriva Biologics, stated that they are delighted to have achieved target enrollment for the VIRAGE Phase 2b trial.
• He also noted that the rapid progress in the VIRAGE trial is a testament to physician interest in VCN-01 and the significant unmet need for an effective treatment for this deadly disease.

Industry Context

The announcement is significant in the context of the broader oncology field, where there is a high unmet need for effective treatments for pancreatic cancer. The use of oncolytic viruses like VCN-01 represents a promising approach to cancer therapy, particularly in combination with standard treatments like chemotherapy and immunotherapy. The company is competing with other companies developing oncolytic viruses such as Replimune, Oncolytics Biotech, Genelux, and CG Oncology.

Comparison to Industry Standards

• The company's VCN-01 is an adenovirus based oncolytic virus, similar to CG Oncology's CG0070, but with a different mechanism of action including the expression of hyaluronidase.
• Replimune's RP1 and RP2 are herpes simplex virus based oncolytic viruses, which are different from Theriva's adenovirus platform.
• Oncolytics Biotech's Pelareorep is a reovirus, which is also different from Theriva's adenovirus platform.
• Genelux's Olvi-Vec is a vaccinia virus, which is also different from Theriva's adenovirus platform.
• The Phase 1 results of VCN-01 in combination with chemotherapy showed an 83% response rate, which is higher than the response rates typically seen with chemotherapy alone in pancreatic cancer, which are in the range of 29% to 41.8%.
• The median overall survival of 20.8 months in the Phase 1 study is also higher than the median overall survival typically seen with chemotherapy alone, which is in the range of 8.5 to 11.1 months.

Stakeholder Impact

• Shareholders will be impacted by the progress of the clinical trial and the potential for future regulatory approvals.
• Employees will be impacted by the company's growth and development.
• Patients with pancreatic cancer may benefit from the development of new treatment options.
• Physicians will be impacted by the availability of new treatment options for their patients.

Next Steps

• The company will conduct regulatory engagements to discuss next steps in VCN-01 clinical development.
• The company will consider a potential interim data analysis.
• The company will explore the potential for converting the Phase 2b study to a Phase 3 registration trial.
• The company will initiate commercial scale manufacturing process development.

Key Dates

Keywords

Oncolytic Virus, Pancreatic Cancer, VCN-01, Clinical Trial, Metastatic PDAC, Orphan Drug Designation, Fast Track Designation, Immunotherapy, Chemotherapy, VIRAGE Trial